JP2007523893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523893A5 JP2007523893A5 JP2006549894A JP2006549894A JP2007523893A5 JP 2007523893 A5 JP2007523893 A5 JP 2007523893A5 JP 2006549894 A JP2006549894 A JP 2006549894A JP 2006549894 A JP2006549894 A JP 2006549894A JP 2007523893 A5 JP2007523893 A5 JP 2007523893A5
- Authority
- JP
- Japan
- Prior art keywords
- atp7a
- secretase
- pharmaceutical composition
- gamma
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04001895 | 2004-01-29 | ||
| EP2004004891 | 2004-05-07 | ||
| PCT/EP2004/013538 WO2005075632A2 (en) | 2004-01-29 | 2004-11-29 | Treatment of neurodegenerative diseases by the use of atp7a-modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007523893A JP2007523893A (ja) | 2007-08-23 |
| JP2007523893A5 true JP2007523893A5 (enExample) | 2008-01-17 |
Family
ID=37818137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549894A Withdrawn JP2007523893A (ja) | 2004-01-29 | 2004-11-29 | Ａｔｐ７ａの使用による、神経変性疾患の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070280927A1 (enExample) |
| EP (1) | EP1718741A2 (enExample) |
| JP (1) | JP2007523893A (enExample) |
| CN (2) | CN1925869A (enExample) |
| AU (1) | AU2004315399B2 (enExample) |
| CA (1) | CA2554362A1 (enExample) |
| WO (1) | WO2005075632A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| GB0700645D0 (en) * | 2007-01-12 | 2007-02-21 | Eisai London Res Lab Ltd | Targets for disease therapy |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| KR101076612B1 (ko) | 2009-01-14 | 2011-10-26 | 재단법인 아산사회복지재단 | 윌슨병 진단용 조성물 |
| AU2019222767A1 (en) * | 2018-02-14 | 2020-08-27 | Deep Genomics Incorporated | Oligonucleotide therapy for Wilson disease |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| CN119979502B (zh) * | 2025-03-13 | 2025-09-26 | 华中科技大学 | 一种防治tau疾病的多肽及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5096815A (en) * | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) * | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
| US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2089661C (en) * | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5582981A (en) * | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| AU4589297A (en) * | 1996-10-07 | 1998-05-05 | Scios Inc. | Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase |
| DE19941039A1 (de) * | 1999-08-28 | 2001-03-01 | Boehringer Ingelheim Pharma | gamma-Sekretase in vitro Testsystem |
-
2004
- 2004-11-29 AU AU2004315399A patent/AU2004315399B2/en not_active Ceased
- 2004-11-29 EP EP04803344A patent/EP1718741A2/en not_active Withdrawn
- 2004-11-29 US US10/587,426 patent/US20070280927A1/en not_active Abandoned
- 2004-11-29 CN CNA2004800423034A patent/CN1925869A/zh active Pending
- 2004-11-29 CN CNA2004800422991A patent/CN1934251A/zh active Pending
- 2004-11-29 JP JP2006549894A patent/JP2007523893A/ja not_active Withdrawn
- 2004-11-29 WO PCT/EP2004/013538 patent/WO2005075632A2/en not_active Ceased
- 2004-11-29 CA CA002554362A patent/CA2554362A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007525491A5 (enExample) | ||
| ATE496021T1 (de) | Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)- phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen | |
| Silletti et al. | Disruption of matrix metalloproteinase 2 binding to integrin αvβ3 by an organic molecule inhibits angiogenesis and tumor growth in vivo | |
| JP2009526754A5 (enExample) | ||
| Yang et al. | MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2 | |
| JP2006523452A5 (enExample) | ||
| Morales et al. | Angiotensin-(1-7) attenuates disuse skeletal muscle atrophy in mice via its receptor, Mas | |
| Parry et al. | Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA | |
| Wang et al. | Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein | |
| NO20070372L (no) | Amidoforbindelser og anvendelse derav som farmasoytiske preparater | |
| JP2006525796A5 (enExample) | ||
| UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
| TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
| BRPI0418029A (pt) | formulação de anticorpos cd40 e métodos | |
| JP2007538008A5 (enExample) | ||
| ATE400573T1 (de) | 1h-imidazochinolinderivate als proteinkinaseinhibitoren | |
| JP2016513640A5 (enExample) | ||
| BR112013018740A2 (pt) | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos | |
| DE60326354D1 (de) | Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form | |
| DE502004011581D1 (de) | Verwendung von rotigotin zur behandlung von depressionen | |
| MXPA05003253A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos. | |
| BRPI0513819A (pt) | inibidores de hsp90 | |
| JP2007523893A5 (enExample) | ||
| DE60301570D1 (de) | 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| ATE491715T1 (de) | Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten |